Abstract
Background: Matrix metalloproteinases (MMPs) are zinc-dependent proteases that degrade components of the extracellular matrix (ECM). In glomerular disease, MMPs are major regulators of ECM degradation as well as structural and functional integrity in the glomerulus. In altered matrix composition diseases, glomerular damage is due to increased degradation of kidney and vessel basement membranes (BMs) by MMPs. MMP -2 and -9 are both considered as the main enzymes that degrade collagen type-IV (coll-IV), which represents the key collagenous component of ECM and constitutes the architectural structure of vessels and glomerular BM. here is growing evidence implicating MMPs in atherosclerosis as well as in cardiovascular disease (CVD) and chronic kidney disease (CKD). Specific endogenous tissue inhibitors of MMPs (TIMPs) are also implicated in CKD, CVD and diabetic nephropathy (DN).
Conclusion: The present review discusses the role of MMPs -2 and -9 in DN, as a leading cause of endstage renal disease and as a model of the link between progressive glomerulosclerosis and MMP expression.
Keywords: Matrix metalloproteinases, gelatinases, diabetic nephropathy, atherosclerosis, proteinuria, glomerulosclerosis.
Current Vascular Pharmacology
Title:Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges
Volume: 15 Issue: 6
Author(s): Grigorios G. Dimas*, Triantafyllos P. Didangelos and Dimitrios M. Grekas
Affiliation:
- 13 Dimokratias Str. Panorama, PC 55236, Thessaloniki,Greece
Keywords: Matrix metalloproteinases, gelatinases, diabetic nephropathy, atherosclerosis, proteinuria, glomerulosclerosis.
Abstract: Background: Matrix metalloproteinases (MMPs) are zinc-dependent proteases that degrade components of the extracellular matrix (ECM). In glomerular disease, MMPs are major regulators of ECM degradation as well as structural and functional integrity in the glomerulus. In altered matrix composition diseases, glomerular damage is due to increased degradation of kidney and vessel basement membranes (BMs) by MMPs. MMP -2 and -9 are both considered as the main enzymes that degrade collagen type-IV (coll-IV), which represents the key collagenous component of ECM and constitutes the architectural structure of vessels and glomerular BM. here is growing evidence implicating MMPs in atherosclerosis as well as in cardiovascular disease (CVD) and chronic kidney disease (CKD). Specific endogenous tissue inhibitors of MMPs (TIMPs) are also implicated in CKD, CVD and diabetic nephropathy (DN).
Conclusion: The present review discusses the role of MMPs -2 and -9 in DN, as a leading cause of endstage renal disease and as a model of the link between progressive glomerulosclerosis and MMP expression.
Export Options
About this article
Cite this article as:
Dimas G. Grigorios*, Didangelos P. Triantafyllos and Grekas M. Dimitrios, Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges, Current Vascular Pharmacology 2017; 15 (6) . https://dx.doi.org/10.2174/1570161115666170202162345
DOI https://dx.doi.org/10.2174/1570161115666170202162345 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Roles for Vasoactive Peptides in Diagnostic and Therapeutic Strategies Against Atherosclerotic Cardiovascular Diseases
Current Protein & Peptide Science Mechanisms of Medial Arterial Calcification in Diabetes
Current Pharmaceutical Design Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?
Current Enzyme Inhibition Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design The Control of Arterial Hypertension: Epidemiological and Economic Challenge
Current Hypertension Reviews Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus
Current Pharmaceutical Design The Possible Role of Saponin in Type-II Diabetes- A Review
Current Diabetes Reviews Diabetes Mellitus and Osteoporosis Correlation: Challenges and Hopes
Current Diabetes Reviews Reducing the Risk of Type 2 Diabetes - Early Identification of High-Risk Individuals and Treatment with Acarbose
Current Diabetes Reviews Dynamics of Diabetes and Obesity: An Alarming Situation in the Developing Countries in Asia
Mini-Reviews in Medicinal Chemistry Advances in Drug Safety
Current Pharmaceutical Design Local Renin-Angiotensin II Systems, Angiotensin-Converting Enzyme and its Homologue ACE2: Their Potential Role in the Pathogenesis of Chronic Obstructive Pulmonary Diseases, Pulmonary Hypertension and Acute Respiratory Distress Syndrome
Current Medicinal Chemistry Telmisartan Inhibits Advanced Glycation End Products (AGEs)-Elicited Endothelial Cell Injury by Suppressing AGE Receptor (RAGE) Expression Via Peroxisome Proliferator-Activated Receptor-γ Activation
Protein & Peptide Letters In Search for the Troponin of the Kidney
Current Medicinal Chemistry Angiotensin Receptor Blockers in Hypertension and Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Chinese Herbal Medicine for Hyperlipidaemia: A Review Based on Data Mining from 1990 to 2016
Current Vascular Pharmacology Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
Current Drug Targets Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications
Current Pharmaceutical Design Dysregulation of Glycogen Synthase Kinase-3 in Skeletal Muscle and the Etiology of Insulin Resistance and Type 2 Diabetes
Current Diabetes Reviews MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets